Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2

Engineered cytokine–based approaches for immunotherapy of cancer are poised to enter the clinic, with IL-12 being at the forefront. However, little is known about potential mechanisms of resistance to cytokine therapies. We found that orthotopic murine lung tumors were resistant to systemically deli...

Descripción completa

Detalles Bibliográficos
Autores principales: Horton, Brendan L., D’Souza, Alicia D., Zagorulya, Maria, McCreery, Chloe V., Abhiraman, Gita C., Picton, Lora, Sheen, Allison, Agarwal, Yash, Momin, Noor, Wittrup, K. Dane, White, Forest M., Garcia, K. Christopher, Spranger, Stefani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619440/
https://www.ncbi.nlm.nih.gov/pubmed/37669107
http://dx.doi.org/10.1172/jci.insight.172728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619440/
https://www.ncbi.nlm.nih.gov/pubmed/37669107
http://dx.doi.org/10.1172/jci.insight.172728

Ejemplares similares